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ABSTRACT
Neonatal immune responses to infection and vaccination are biased toward TH2 at the cost of proinflammatory TH1 responses
needed to combat intracellular pathogens. However, upon appropriate stimulation, the neonatal immune system can induce
adult-like TH1 responses. Here we report that a new class of vaccine adjuvant is especially well suited to enhance early life immu-
nity. The GVI3000 adjuvant is a safe, nonpropagating, truncated derivative of Venezuelan equine encephalitis virus that targets
dendritic cells (DCs) in the draining lymph node (DLN) and produces intracellular viral RNA without propagating to other cells.
RNA synthesis strongly activates the innate immune response so that in adult animals, codelivery of soluble protein antigens
induces robust humoral, cellular, and mucosal responses. The adjuvant properties of GVI3000 were tested in a neonatal BALB/c
mouse model using inactivated influenza virus (iFlu). After a single immunization, mice immunized with iFlu with the GVI3000
adjuvant (GVI3000-adjuvanted iFlu) had significantly higher and sustained influenza virus-specific IgG antibodies, mainly
IgG2a (TH1), compared to the mice immunized with antigen only. GVI3000 significantly increased antigen-specific CD4
 and
CD8 T cells, primed mucosal immune responses, and enhanced protection from lethal challenge. As seen in adult mice, the
GVI3000 adjuvant increased the DC population in the DLNs, caused activation and maturation of DCs, and induced proinflam-
matory cytokines and chemokines in the DLNs soon after immunization, including gamma interferon (IFN-), tumor necrosis
factor alpha (TNF-), granulocyte colony-stimulating factor (G-CSF), and interleukin 6 (IL-6). In summary, the GVI3000 adju-
vant induced an adult-like adjuvant effect with an influenza vaccine and has the potential to improve the immunogenicity and
protective efficacy of new and existing neonatal vaccines.
IMPORTANCE
The suboptimal immune responses in early life constitute a significant challenge for vaccine design. Here we report that a new
class of adjuvant is safe and effective for early life immunization and demonstrate its ability to significantly improve the protec-
tive efficacy of an inactivated influenza virus vaccine in a neonatal mouse model. The GVI3000 adjuvant delivers a truncated,
self-replicating viral RNA into dendritic cells in the draining lymph node. Intracellular RNA replication activates a strong innate
immune response that significantly enhances adaptive antibody and cellular immune responses to codelivered antigens. A signif-
icant increase in protection results from a single immunization. Importantly, this adjuvant also primed a mucosal IgA response,
which is likely to be critical for protection during many early life infections.
The World Health Organization (WHO) estimates approxi-mately 2 million deaths in neonatal and infant humans (1
year of age) every year worldwide due to acute infections caused by
a limited number of pathogens (1). The availability of effective
early life vaccines against those agents would have a significant
impact on disease burden in neonates and infants, who are espe-
cially vulnerable to infectious diseases and in whom the immune
responses generated by most currently available early life vaccines
are suboptimal. The need for effective early life vaccines is espe-
cially important in resource-poor countries, where the period im-
mediately after childbirth is often the only point of contact with
the health care system.
A major obstacle in the development of early life vaccines is
that the neonatal immune system is geared more toward a
TH2 response at the cost of TH1 responses needed to combat in-
tracellular pathogens (2, 3). The neonatal antibody response to
conventional subunit and live attenuated vaccine antigens is of
limited magnitude and duration, and CD8 T-cell responses also
are reduced compared to adults (4–6). The predisposition of the
neonatal immune system toward a TH2 response is caused by the
suboptimal innate immune response, with delayed maturation of
neonatal dendritic cells (DCs) and limited production of inflam-
matory cytokines, which leads to inefficient antigen presentation
and stimulation of naive T cells (7–10). Therefore, many vaccines
that are effective in adults are poorly immunogenic in early life,
hence requiring multiple booster immunizations (5).
Influenza viruses cause millions of annual infections world-
wide, with up to 40,000 deaths reported in the United States alone
(11). Newborns and infants are at higher risk for influenza-related
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mortality because of their immature immune systems, which can
often lead to severe viral pneumonitis or bacterial superinfection
(12). Protection from influenza viruses, like most respiratory vi-
ruses, is optimally conferred through virus-specific antibodies,
such as IgG and IgA. However, antibody-mediated protection
does not fully protect against heterologous strain infection due to
the variability in the surface glycoproteins (13). On the other
hand, T-cell epitopes are highly conserved across influenza virus
strains, and a robust T-cell response can induce broader protec-
tion (14). Currently available influenza vaccines—tetravalent in-
activated (TIV) or live attenuated (LAIV)—are not recommended
for use in infants who are less than 6 months old (15). While LAIV
immunization has been more effective in young children (6 to 11
months) compared to TIV immunization, it has been associated
with safety concerns, such as increased rate of wheezing and hos-
pitalization (16, 17). Therefore, the development of inactivated
influenza vaccines, with improved efficacy in infants less than 6
months of age is urgently needed. In this study, we chose inacti-
vated influenza virus as a model antigen.
Studies have shown that upon appropriate stimulation, the
otherwise “immature” neonatal immune system has the capacity
to induce adult-like TH1 immune responses and protect against
infections (2). The best example of a neonatal TH1 vaccine is the
Mycobacterium tuberculosis bacillus Calmette-Guerin (BCG) vac-
cine against tuberculosis, which induces strong, adult-like gamma
interferon (IFN-) responses and a protective TH1 response in
newborns. The WHO has recommended the BCG vaccine for im-
munization immediately after birth (18). An increased interest in
developing and testing TH1-inducing adjuvants for early life im-
munizations has resulted in a number of studies in human cord
blood cells and in neonatal animal models, using cytokines and
ligands of Toll-like receptors (TLRs). Stimulation of CD4 T cells
from human umbilical cord blood with recombinant interleukin
12 (IL-12) resulted in the induction of adult-like IFN- responses
(19). TLR7/8 agonists, R848, or TLR8 agonist VTX-294 showed
TH1 responses, indicated by production of cytokines tumor ne-
crosis factor alpha (TNF-), IL-1, and IL-12 secreted by antigen-
presenting cells (APCs) from newborn cord blood (20, 21). CpG,
a TLR9 agonist, can induce adult-like DC and T-cell activation,
while failing to induce adult-like antibody (Ab) responses (22).
IC31 (Intercell AG), a two-component adjuvant consisting of an
antibacterial peptide and the TLR9 agonist ODN1a, when com-
bined with a pneumococcal conjugate vaccine, enhances protec-
tive immunity in neonatal mice (23). A synthetic water-in-oil
emulsion-based adjuvant, CRL-8941 (24), and complete Freund’s
adjuvant (CFA) (25), induced adult-like TH1 immune responses
in neonatal mice, indicated by induction of antigen-specific IgG2a
antibodies (an indicator of a TH1 response in BALB/c mice)
and/or IFN--secreting splenocytes. However, CRL-8941 was re-
ported by the authors to cause “significant local toxicity” in neo-
natal mice, while CFA is universally toxic. Therefore, there is a
continued need for safe and effective adjuvants that can promote
strong, balanced, and protective newborn immune responses to
new and existing vaccines. The two adjuvants currently approved
as components of human vaccines, alum and MF59, are both in-
ducers of TH2-polarized immune responses (26). Therefore, an
adjuvant promoting a TH1 response might be useful in inducing a
balanced vaccine response by the already TH2-biased neonatal im-
mune system.
In this study, we investigated the effectiveness of a new class of
adjuvants in early life vaccination. The novel adjuvant GVI3000 is
derived from an alphavirus genome. Venezuelan equine enceph-
alitis (VEE) virus is a positive-sense, single-stranded RNA virus
representative of the alphavirus genus. Its 11.5-kb RNA genome
encodes four nonstructural proteins and three structural proteins,
the latter expressed from a 26S subgenomic promoter. Although
the adjuvant properties of attenuated VEE virus have been sug-
gested for some time (27, 28), our group has developed and char-
acterized propagation-incompetent VEE replicon particles with
strong adjuvant activity (29), and analogous adjuvants have been
derived from Semliki Forest virus (30) and Sindbis virus (R. Mik-
kelsen and R. E. Johnston, unpublished data). VEE adjuvant par-
ticles have been referred to as nVRP (29, 31) or GVI3000 (32), and
they contain a truncated VEE virus genome that includes the 5=
and 3= untranslated regions (UTRs) and the nonstructural genes
but lack the 26S subgenomic promoter and the structural protein
genes. When inoculated into adult mice by subcutaneous, intrad-
ermal, or intramuscular routes with a number of soluble (ovalbu-
min [OVA] or keyhole limpet hemocyanin [KLH]) or inactivated
particulate antigens (norovirus, poliovirus, or influenza viruses),
these adjuvant particles can enhance humoral, cellular, and mu-
cosal immune responses (29, 31–33). Additionally, enhanced pro-
tection against influenza and dengue viruses was demonstrated in
a macaque model (34, 35). Upon subcutaneous immunization of
mice, GVI3000 particles enter Langerhans cells (LC) at the site of
inoculation where viral RNA replication and LC activation pre-
sumably occurs (36). These infected immune cells then rapidly
migrate to the draining lymphoid node(s) (DLN). Alternatively,
GVI3000 particles can migrate directly to DLNs, where they pref-
erentially target DCs (36, 37). In both human- and mouse-derived
DCs, in vitro studies have shown an upregulation of costimulatory
molecules as well as secretion of proinflammatory cytokines, such
as type I IFN, IL-6, and TNF after infection (37–39). In adult mice,
cytokine secretion was observed systemically and in the DLNs as
soon as 6 h after GVI3000 inoculation (unpublished observation).
Tonkin et al. (40) demonstrated that DCs infected ex vivo with
GVI3000, when inoculated into adult BALB/c mice, were suffi-
cient to enhance in vivo systemic, mucosal, and cellular responses.
Furthermore, the immune cells most frequently targeted and re-
cruited to the draining lymph node were monocyte-derived in-
flammatory DCs.
On the basis of the properties of the GVI3000 adjuvant, we
predicted that it might be well suited as a TH1-polarizing vaccine
adjuvant to enhance neonatal immunization. We hypothesize that
GVI3000 can induce a sufficiently strong DC activation to over-
come the neonatal limitation to induce a Th1 response, hence
promoting an “adult-like immune response,” shifting the neona-
tal immune system to a more balanced TH1-TH2 response, induc-
ing mucosal and T-cell responses, and improving vaccine efficacy
in neonates.
In this study, we used a 7-day-old BALB/c neonatal mouse
model, which has been reported to more closely resemble the stage
of immune maturation and immune-function limitations in hu-
man neonates (5). We immunized 7-day-old and adult mice with
inactivated influenza virions (iFlu) in the presence of GVI3000
adjuvant and compared the effect of the adjuvant on induced
adaptive and innate immune responses after a single immuniza-
tion of the two age groups. Antigen-specific antibody responses
were significantly enhanced by the adjuvant and lasted for at least
several months. iFlu with the GVI3000 adjuvant (GVI3000-adju-
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vanted iFlu) was also able to induce antigen-specific T cells in the
DLNs of immunized neonates and primed a mucosal IgA re-
sponse. The addition of the GVI3000 adjuvant to the iFlu vaccine
resulted in a significant increase in protection from a lethal chal-
lenge. Furthermore, as observed in adults, inflammatory DCs
were the most frequently recruited and targeted immune cells in the
DLNs. The proinflammatory innate immune response profile was
similar to that in immunized adult mice, indicating that GVI3000
exploits similar pathways in both neonates and adults and can over-
come any shortcomings in the neonatal immune system. These find-
ings support the conclusion that codelivery of GVI3000 and an inac-
tivated vaccine can significantly improve immune responses and
protection against challenge in neonatal mice.
MATERIALS AND METHODS
Cells. Vero81 cells were obtained from the American Type Culture Col-
lection (ATCC). The Vero81 cells were maintained at 37°C in Dulbecco’s
modified Eagle’s medium (DMEM) with nutrient mixture F12 medium
supplemented with 10% fetal calf serum, penicillin-streptomycin (100
U/ml), and streptomycin (100 g/ml) in the presence of 5% CO2. L929
mouse fibroblast cells (ATCC CCL-1) were maintained in DMEM sup-
plemented with 10% fetal bovine serum (FBS), penicillin-streptomycin
(100 U/ml), and 0.29 mg/ml of L-glutamine. Chicken red blood cells
(CRBCs) were obtained from Charles River Laboratories (catalog no.
10100767) and stored at 4°C for hemagglutination inhibition assays.
Viruses and vaccine antigens. Live influenza A/PR/8/34 virus (catalog
no. 10100374) and formalin-inactivated influenza virus A/PR/8/34 (iFlu)
(catalog no. 10100782) were obtained from Charles River Laboratories
and stored at 	80°C until use.
Adjuvant VEE replicon particles (GVI3000). The production of
GVI3000 adjuvant particles, also known as nVRP, has been described
previously (31, 41, 42). Briefly, in vitro-transcribed VEE replicon RNA
genome, together with two helper RNAs— expressing viral structural
genes in trans—were coelectroporated into Vero81 cells. GVI3000 parti-
cles were collected in the culture medium 24 h after electroporation. These
particles contain only replicon RNA and exclude helper RNAs, which lack
the virus-specific packaging signal, rendering these particles propagation
incompetent. Cytopathic effect testing was performed on each production
batch to confirm the absence of detectable propagation-competent virus
that could arise as a contaminant due to RNA recombination. The adju-
vant particles were concentrated by ultracentrifugation through a 20%
sucrose cushion, suspended in phosphate-buffered saline (PBS) contain-
ing 1% human serum albumin, and stored at 	80°C until use. The titers
of GVI3000 infectious particles were then determined by infection of Vero
cells as measured by immunofluorescence staining of VEE nonstructural
proteins, using polyclonal sera from mice immunized with VEE nonstruc-
tural protein 2.
Two modalities of VEE replicon RNA were packaged in this study: (i)
GVI3000 replicon RNA, which encodes the 5= and 3= untranslated regions
(UTRs) flanking the viral nonstructural genes but lacks the sequence be-
tween the nsP4 stop codon (5 nucleotides [nt] before the 26S mRNA
transcription start site) and the beginning of the 118-nt 3= UTR (31); (ii)
GVI3000-GFP replicon RNA, which encodes the viral nonstructural pro-
tein genes and also the sequence for green fluorescent protein (GFP) un-
der the control of the viral 26S subgenomic promoter. GVI3000-GFP was
used as reporter particles to identify GVI3000-infected cells. All known
cis-acting signals for RNA replication were included in the GVI3000 ge-
nomes. All replicon particles were packaged using wild-type VEE (V3000)
envelope sequences (43).
Mice and immunizations. Pregnant and adult BALB/c mice were pur-
chased from Charles River and were housed at the Global Vaccines Inc.
animal facility. All studies were carried out in accordance with the recom-
mendations of the Guide for the Care and Use of Laboratory Animals (44).
All animal protocols were approved by the Global Vaccines, Inc. Institu-
tional Animal Care and Use Committees (IACUC) prior to performing
experiments. Pregnant mice were closely monitored for date and approx-
imate time of delivery.
Seven days after birth, neonatal mice were injected in both rear foot-
pads with PBS or one of the following formulations: iFlu alone, iFlu mixed
with alum (Alhydrogel [2%]; Invivogen) or iFlu mixed with GVI3000.
The immunization volume was 10 l (total) (5 l in each rear footpad).
Mice were immunized once unless otherwise stated. Adult control mice (6
to 8 weeks old) were immunized in both rear footpads (10 l/footpad)
after being anesthetized by intraperitoneal (i.p.) injection with a 4/1 mix-
ture (vol/vol) of ketamine (50 g/g of body weight) and xylazine (15 g/g
of body weight). Mice were observed daily for a week for any adverse
reaction to the immunization.
Flu challenge. The mouse flu challenge model used here has been
described elsewhere (45). Three weeks after neonatal immunization, mice
were challenged with 106 50% egg infectious doses (EID50) of influenza
virus strain PR/8/34 (Charles River, MA). The challenge dose represented
the lowest dose that was 100% lethal in control mice immunized with
diluent, and it was optimized in a separate experiment. The virus was
diluted in a total volume of 50 l, and 25 l was introduced into each naris
under light isoflurane anesthesia. Mice were observed for 11 days for
weight, morbidity, and mortality. The animals were monitored for clinical
signs of disease, including ruffling, hunching, signs of dehydration (con-
cave dorsal surface), and reduced spontaneous mobility. To assess protec-
tion from postchallenge influenza virus replication in the nose, mice were
neonatally immunized, and 5 weeks later, mice were challenged intrana-
sally with 106 EID50 of influenza virus strain PR/8/34. At 48 h postchal-
lenge, mice were euthanized, and nasal tissues were harvested from the tip
of the nose to the anterior of the eye sockets, as described before (29, 46).
Nasal tissue was collected in 10% FBS medium and centrifuged, followed
by storage in TRIzol at 	80°C until RNA isolation.
RNA isolation and real-time PCR. RNA extraction from nasal tissues
was performed using the PureLink RNA minikit (Ambion) according to
the manufacturer’s protocol. RNA samples were then treated with DNase
using the Turbo DNA-free kit (Ambion), following the manufacturer’s
protocol. Quantification of influenza virus strain PR8 hemagglutinin
(HA) negative-strand RNA levels in the nasal tissues was performed by
reverse transcription-PCR (RT-PCR) as has been described previously
(47). Briefly, cDNAs were prepared using reverse transcription with oli-
go(dT). RT-PCR was performed using TaqMan gene expression assays
(Applied Biosystems) and gene-specific primers and probes (Life Tech-
nologies). The samples were then run on an ABI Prism 7000 real-time
PCR system. During each reaction, a cycle threshold (CT) value for the
target gene of interest was generated, which was then normalized to the CT
value of the housekeeping gene (glyceraldehyde-3-phosphate dehydroge-
nase [GAPDH]) yielding a 
CT value. The 
CT value of the nVRP-in-
fected sample was then subtracted from the 
CT value of the antigen-only
sample, resulting in a 

CT value. Fold increase in mRNA expression in
nVRP group relative to the expression level in antigen-only group were





The HA-specific primers (forward [ACTGGACCTTGCTAAAACCC]
[starting at nt 772]; reverse [CATTGATGCGTTTGAGGTGATG])
and probes containing a 5’ fluorescent reporter (6-FAM), a 3’ quencher
(IABkFQ), and an internal quencher (ZEN) (/6-FAM/CCCAAAGCC/
ZEN/TCTACTCAGTGCGAA A/3IABkFQ/) for RT-PCR were designed
and obtained from Integrated DNA Technologies (IDT). Additionally,
PR8 HA negative-strand RNA standards were prepared from the influ-
enza virus stock used for infection and run on each sample plate. For the
analysis, CT value from each sample was plotted on the standard curve to
obtain PR8 viral titer. All CT values were normalized to the 18S house-
keeping gene.
Analysis of antigen-specific IgG in serum and IgA in fecal extracts by
ELISA. Mouse serum samples were collected at 3, 6, 9, and 15 weeks after
immunization and stored at 	20°C. For preparation of fecal extracts, fecal
pellets collected 10 to 14 days after the booster immunization were sus-
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pended at 0.2 g/ml and disrupted by vortex mixing at 4°C in PBS contain-
ing 10% goat serum and 1 protease inhibitors (catalog no. 11873580001;
Roche). Samples were centrifuged, and supernatants were filtered
through 0.22-m filters. Antigen-specific IgG and IgA antibodies were
detected by enzyme-linked immunosorbent assay (ELISA) on 96-well
high binding plates (Thermo Scientific) coated with 4 g/ml iFlu in PBS.
Sera and fecal extracts were added to plates in serial dilutions. Antigen-
specific antibodies were detected with horseradish peroxidase-conjugated
antibodies specific for mouse IgG (Southern Biotech) or mouse IgA
(Southern Biotech) followed by the addition of SureBlue (3,3=,5,5=-te-
tramethylbenzidine [TMB] microwell peroxidase substrate; KPL) for 30
min. Endpoint titers were determined as the last sample dilution that
generated an optical density at 450 nm (OD450) reading of greater than
0.2. For determination of total IgA levels in fecal extracts, 96-well plates
were coated with 0.4 g/ml rabbit anti-mouse IgA (Invitrogen), ELISAs
were performed as described above, and a standard curve was generated
from dilutions of purified murine IgA (Sigma). This standard curve was
used to determine the concentration of both antigen-specific and total IgA
in fecal extracts.
HAI. Influenza virus-specific hemagglutination inhibition assay
(HAI) has been described elsewhere (48). Complement was inactivated by
heating the serum sample at 56°C for 30 min. Mouse serum was then
preadsorbed with 1% suspension of chicken red blood cells resulting in a
1:5 dilution. Briefly, four hemagglutination units (HAU) of influenza vi-
rus strain PR8 in 50 l was mixed with 2-fold serial dilutions of pread-
sorbed mouse serum (50 l per dilution) and incubated at room temper-
ature for 30 min (starting dilution 1:10). Fifty microliters of a 1%
suspension of CRBCs was then added to each well. In serum dilutions with
anti-HA antibody, virus was bound by antibody and was not available to
agglutinate the CRBCs. The maximal reciprocal serum dilution where
agglutination was completely inhibited is reported as the HAI titer.
IFN- bioassay. The levels of biologically active type I IFN in mouse
sera were determined using an interferon bioassay as previously described
(49). Briefly, L929 mouse fibroblasts were seeded in 96-well plates. Mouse
serum samples, including the standards, were acidified to a pH of 2.0
overnight, then neutralized to a pH of 7, and added to cells in serial 2-fold
dilutions. After 24-h incubation, 105 PFU of encephalomyocarditis virus
(EMCV) was added to each well. Twenty-four hours postinfection, cell
viability was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) (Sigma), and the absorbance was read on
a microplate reader at 570 nm. To obtain type I IFN value in international
units per milliliter (IU/ml), the absorbance from each sample was com-
pared to a dilution series of IFN- standard (catalog no. NR-3076; BEI)
present in each plate.
Surface staining of cells from draining lymph nodes (DLNs). At the
indicated time points, both draining popliteal lymph nodes from each
animal were harvested, combined, and homogenized through 40-m cell
strainers. Cells were washed, counted by using a hemocytometer, and
stained at 4°C for the desired surface receptors with a selection of the
following fluorochrome-conjugated antibodies specific for CD3, CD4,
CD8, CD11b, CD11c, CD40, CD80, CD86, major histocompatibility
complex class II (MHCII) (eBioscience), Ly-6G and Ly-6C (BD Biosci-
ence) in PBS containing 1% bovine serum albumin (1% BSA/PBS). After
the cells were stained, they were washed and then fixed in 2% paraformal-
dehyde in PBS for 15 min at room temperature. The cells were analyzed on
an Accuri C6 flow cytometer (BD).
IFN- ELISPOT assay. IFN- enzyme-linked immunospot (ELISPOT)
assay was performed to measure influenza virus PR8 HA-specific IFN--
secreting CD4 and CD8 cells in the popliteal draining lymph nodes and
spleens of immunized mice. Mouse IFN- capture antibody (R&D Sys-
tems) was incubated on nitrocellulose membrane plates (96 well; Milli-
pore) overnight at 4°C. Before the addition of cells, the plates were washed
and blocked for at least 2 h with complete RPMI 10 (10% fetal bovine
serum) at 37°C. Single-cell suspensions in RPMI 10 (2.5  105 or 5  105
cells per well) from either popliteal draining lymph node or spleen were
then added to the plates. Additionally, feeder cells (2.5  105 cells per well)
from a naive adult BALB/c mouse spleen were added to all wells. Finally,
CD4 (HA from amino acids 110 to 120 [HA 110-120]; SFERFEIFPKE)
and CD8 (HA 518-526; IYSTVASSL) immunodominant HA peptides
from AnaSpec were added to the appropriate cells for 36 h. The cells were
removed from plates and washed, a biotinylated mouse IFN- detection
antibody (R&D Systems) was added to the plates, and the plates were
incubated for another 36 h at 4°C. Membranes were again washed, incu-
bated with a streptavidin-alkaline phosphatase conjugate for 2 h at room
temperature. The plates were washed, and spots were developed following
the addition of 5-bromo-4-chloro-3-indolylphosphate (BCIP)/Nitro
Blue Tetrazolium (NBT) substrate. The plates were scanned by Cellular
Technologies Ltd. (Shaker Heights, OH). Assay background values were
obtained from sample wells with no peptide/protein stimulation and were
subtracted from the values obtained with the influenza virus HA peptide.
Data are normalized to the number of antigen-specific IFN--secreting
cells per 106 cells.
TCID50 assay. Virus titers in the lungs were determined by 50% tissue
culture infectious dose (TCID50) assay on MDCK cells. Lungs collected on
day 3 postchallenge were homogenized, serially diluted 10-fold, and then
added in quadruplicate to cells in a 96-well plate. After 48 h of incubation,
an influenza hemagglutination assay using 5% chicken red blood cells was
performed on the medium from each well. TCID50 titers were determined
using the Reed and Muench calculator (50).
Multiplex analysis for cytokine expression in the DLNs. To deter-
mine cytokine levels in the DLNs of mice immunized with iFlu alone or
with GVI3000, the draining popliteal lymph nodes from each mouse were
harvested, combined, and placed in 100 l of PBS containing 1 protease
inhibitors (catalog no. 11873580001; Roche). The lymph nodes were me-
chanically homogenized with a pestle, followed by centrifugation at 4°C.
Supernatant was transferred to another tube and frozen on dry ice. Cyto-
kine levels in the samples were determined by Luminex-based multiplex
assay. For one experiment, the levels of 18 cytokines were tested using the
Milliplex MAP mouse cytokine/chemokine magnetic bead panel (EMD
Millipore, Billerica, MA). The assay was performed by the Center for
Gastrointestinal Biology and Disease’s Immunotechnologies Core at the
University of North Carolina at Chapel Hill. Multianalyte profiling was
performed on a Bio-Plex 200 system with an XY platform and high-
throughput fluidics (Bio-Rad Laboratories, Hercules, CA). Calibration
and validation microspheres for classification and reporter readings, as
well as optics and fluidics verification, were also obtained from Bio-Rad.
The instrument’s sheath fluid was prepared from concentrate obtained
from Luminex (Luminex Corporation, Austin, TX). Fluorescence data
were acquired using Bio-Plex Manager 6.0 software, and all cytokines
were successfully detected. Data analysis was performed using the same
software, and a best-fit standard curve was obtained using either four- or
five-parameter regression, from which the sample concentrations were
derived. Cytokines that were undetectable were assigned a value of half of
the lowest limit of detection as listed in the Milliplex MAP mouse cyto-
kine/chemokine magnetic bead panel kit manual.
Statistical analysis. Antibody titers and cytokine values were evalu-
ated for statistically significant differences by either the analysis of vari-
ance (ANOVA) or Mann-Whitney test (GraphPad Prism). Statistical sig-
nificance is reported as follows: , P  0.05; , P  0.01; , P  0.001.
RESULTS
GVI3000 safely enhances humoral immune responses to inacti-
vated flu virus (iFlu) in neonatal mice. To determine the adju-
vant effect of GVI3000 on humoral responses to iFlu in neonatal
mice, we assessed the magnitude, duration, and quality of serum
antibodies and induction of fecal antibody responses by iFlu alone
or formulated with the GVI3000 adjuvant. Seven-day-old BALB/c
mice from one litter received a single immunization with 2 g of
iFlu mixed with GVI3000 (105 IU), while mice from a second litter
were immunized with 2 g of iFlu only. The mice were monitored
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daily for local reactogenicity, morbidity, and mortality. No ad-
verse effects of immunization with iFlu alone or with GVI3000
(iFlu-GVI3000) were observed. Over the past several years, ap-
proximately 2,000 adult mice and over 350 neonatal mice have
been immunized with GVI3000 adjuvant without any observable
signs of adverse reaction (29, 31, 32, 40, 46, 51, 52; D. Tonkin, B.
Steil, and P. Jorquera, personal communications). Influenza vi-
rus-specific IgG ELISA antibody titers in the iFlu-only group were
modest and did not increase between 6 and 15 weeks postimmu-
nization (Fig. 1A). In the GVI3000-adjuvanted group, the titers
were significantly higher for all time points tested compared to the
iFlu-only group. From week 6 to week 15, the titers in GVI3000-
adjuvanted mice continued to increase significantly (P  0.05)
compared to week 3 (Fig. 1A). Additionally, week 15 titers were
significantly higher than week 6 titers. The influenza virus-specific
IgG2a titers (indicator of TH1 response) in the GVI3000-adju-
vanted immunization group were significantly higher at 3, 6, and
15 weeks (Fig. 1B), while the IgG1 (indicator of TH2 response)
titers were comparable between the groups (Fig. 1C), suggesting
that the GVI3000 adjuvant-mediated enhanced IgG response was
predominantly in the IgG2a subclass. We performed our studies
in the BALB/c strain of mice, although previous results from our
lab have shown that adult C57BL/6, 129 Sv/Ev, and other strains of
mice produce a similar TH1-biased response upon GVI3000 im-
munization.
Previous studies have suggested the important role mucosal
immunity plays in protecting against influenza virus, which pri-
marily infects and provokes inflammation at respiratory mucosal
sites (53). A unique feature of the GVI3000 adjuvant is its ability to
induce—in adult mice—an antigen-specific mucosal IgA anti-
body response after a nonmucosal route of immunization (29,
46). We chose to measure the IgA response in the fecal pellets of
immunized mice, as IgA detection in fecal pellets is often a more
reliable and unambiguous measure of mucosal response than ex-
amining nasal or tracheal lavage fluid. Additionally, it is known
that mice have a common mucosal system, in which responses at
one mucosal tissue likely mirrors those in other mucosal sites (54).
Published studies of adult BALB/c mice have shown that induc-
tion of antigen-specific IgA in GVI3000-adjuvanted mice was sig-
nificantly enhanced in fecal extracts, similar to the increase in the
nasal epithelium (29, 51). To address whether GVI3000 can prime
the induction of antigen-specific mucosal IgA in early life immu-
nizations, neonatal mice were primed with iFlu alone or with iFlu
plus GVI3000, and 10 weeks later, they were boosted with iFlu
antigen only. The amount (nanogram of influenza virus-specific
IgA/microgram of total IgA) of influenza virus-specific IgA anti-
body found in fecal materials 10 days after the boost was measured
by ELISA (Fig. 1D). Presenting the IgA data as nanogram of influ-
enza virus-specific IgA/microgram of total IgA allows for normal-
ization of the fecal pellet size, which can vary between the groups
FIG 1 GVI3000 is an effective adjuvant to iFlu after a single dose in mice immunized as neonates. Three to five 7-day-old BALB/c mice per experimental group
were primed through footpad (f.p.) injection with iFlu (2 g) with 105 IU of GVI3000 (black bars) or without GVI3000 (white bars). (A to C) Three, 6, 9, and 15
weeks after the immunization, influenza virus-specific IgG (A) and IgG1 (B) and IgG2a (C) antibodies were measured in serum by ELISA. (D) GVI3000 induces
mucosal immune response in neonatally primed mice. Five or six 7-day-old BALB/c mice were primed through f.p. injection with iFlu (1 g) only or with 105
IU of GVI3000. Ten weeks after the mice were primed, all groups were boosted with iFlu (1 g) alone. Ten days after the boost, antigen-specific IgA were
measured in fecal extracts by ELISA. The amount of IgA produced is presented as nanograms of influenza virus-specific IgA per microgram of total IgA. (E)
Antibodies with influenza virus hemagglutination inhibition activity were measured by hemagglutination inhibition assay (HAI) at 6 weeks after the immuni-
zation. All data are presented as means plus standard errors of the means (SEM) (error bars). Values that are significantly different from the value for iFlu alone
by the Mann-Whitney test are indicated by bars and asterisks as follows: *, P  0.05; **, P  0.01.
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of mice, genders, and within the same group sampled at different
times, making it a reliable and accurate measure (55). While the
signal for iFlu-only induction of IgA was at the background level,
a significantly larger amount of influenza virus-specific IgA was
observed in mice that had GVI3000 adjuvant in the prime. Impor-
tantly, the amount of influenza virus-specific IgA in the adju-
vanted group was not significantly lower than that found in adult
mice (1.59 ng in neonates compared to 1.74 ng influenza virus-
specific IgA per g total IgA in adults), when mice from both age
groups were compared in the same experiment (data not shown).
To further assess the quality of the influenza virus-specific an-
tibodies being induced, we measured the ability of the antibodies
in the sera to inhibit hemagglutination of chicken red blood cells
using an HA binding inhibition assay (HAI). We included an ex-
perimental group adjuvanted with alum (Alhydrogel, 1:5), a well-
characterized benchmark adjuvant, formulated as indicated by
the manufacturer. Six weeks after immunization, HAI titers in the
GVI3000-adjuvanted group (geometric mean titer [GMT]  24)
were significantly higher than those in the iFlu-only group
(GMT  10). The HAI titer in the alum-adjuvanted group
(GMT  16) was not significantly different from either GVI3000
or no-adjuvant groups (Fig. 1E). At other time points (3 and 15
weeks), we did not observe any difference in HAI titers between
the immunization groups (data not shown).
In summary, GVI3000 adjuvant significantly enhanced anti-
body responses to iFlu in neonatally immunized mice. Enhanced
serum antibodies were mostly of the IgG2a class and had HAI
activity. While antibody titers continued to increase during the 15
weeks of study, these titers were of much lower magnitude than
those induced by the same vaccine regime in adult mice (unpub-
lished observation). While this was true for serum antibodies after
one dose, the ability of the adjuvant to prime a mucosal response
seemed as effective in neonates as in adults.
GVI3000 adjuvant induces antigen-specific CD4 and CD8 T
cells after a single immunization in neonatal mice. While the
contribution of T-cell immunity to protection against influenza
remains a matter of debate, the flu model was utilized to deter-
mine whether GVI3000 can enhance the induction of antigen-
specific T cells in neonatal mice. We chose to examine the T-cell
responses in the DLNs (popliteal) as opposed to the more distal
LNs (such as mediastinal). T-cell responses are present in distal
LNs at reduced but still detectable levels relative to the DLN re-
sponses. In these initial neonatal studies of immunity induced by
GVI3000, it was prudent to first evaluate responses in the DLNs
where we anticipate the most robust response, with the expecta-
tion that immunity detected in one tissue will correlate with im-
mune memory throughout the animal. Groups of three 7-day-old
mice were immunized in both rear footpads with iFlu alone (2 g)
or with iFlu mixed with GVI3000 (105 IU). In this experiment, a
group adjuvanted with alum was also included. Eight days after
immunization, animals were sacrificed, and single-cell suspen-
sions were prepared from the pooled (two per mouse) popliteal
DLNs. Cells were evaluated for the presence of IFN--secreting
CD8 and CD4 T cells following stimulation with immunodomi-
nant HA peptides. We chose to detect HA-specific T cells instead
of T cells to other antigens (such as nucleoprotein [NP]), as we
were not sure which proteins, other than HA, were intact in the
inactivated influenza virus antigen. Furthermore, based on our
experience, adult BALB/c mice are capable of inducing T cells
specific for multiple antigens after a multivalent immunization,
indicating that the T-cell response will most likely be not limited
to HA antigen only. Animals receiving iFlu alone produced unde-
tectable to very low levels of influenza virus-specific CD4 and
CD8 T cells. However, iFlu formulated with GVI3000 adjuvant
resulted in a significant increase of both CD4 and CD8 T cells
(Fig. 2). Although the alum group had low but detectable amounts
of CD4 T cells and CD8 T cells, they were significantly lower
than the GVI3000-immunized group. Taken together, these re-
sults strongly suggest that the GVI3000 adjuvant can promote the
induction of a CD8 T-cell response in the TH2-polarized neona-
tal immune system.
Neonatal mice immunized with GVI3000-adjuvanted iFlu
vaccine have reduced morbidity and mortality and reduced
early postchallenge virus titers in nose and lungs. Two indepen-
dent flu challenge experiments were performed. In the first exper-
iment, four litters of mice were immunized on day 7 after birth
with either PBS (n  8), iFlu only (n  5), iFlu with GVI3000 (105
IU) (n  5), or iFlu formulated with alum (1:5) (n  7). Three
weeks after immunization, the mice received a lethal challenge by
intranasal inoculation with 106 EID50 of influenza virus A/PR/8/
34. The mice were monitored daily for 11 days for weight loss,
morbidity, and mortality. Figure 3A shows the survival curves. All
the PBS-immunized control mice succumbed to the challenge. All
mice that received a single GVI3000-adjuvated immunization
were protected. Three out of 7 mice that received alum-adju-
vanted iFlu antigen survived, while 2 out of 5 mice in the group
immunized with iFlu only survived. A repeat challenge experi-
ment using a different stock of live influenza virus was done with
three immunization groups: PBS control (n  6), iFlu only (n 
11), and iFlu with GVI3000 (n  11). In this experiment, mice
were monitored for 25 days. No protection was observed in PBS-
immunized control mice or iFlu-only-immunized mice, while 7
out of 11 mice survived in the GVI3000-adjuvanted group (Fig.
3B). Taken together, the two experiments demonstrate that the
GVI3000-adjuvanted vaccine outperforms vaccine alone but that
the vaccine adjuvanted with alum was no more protective than
FIG 2 GVI3000 adjuvant promotes influenza virus-specific cellular immune
response in DLNs from neonatal mice after a single neonatal immunization.
Three 7-day-old BALB/c mice were primed in both rear footpads (f.p.) with
iFlu (2 g) in the presence or absence of 105 IU of GVI3000. As a control
adjuvant, three mice from one litter were immunized with alum (1:2 by vol-
ume). Eight days after immunization, both popliteal draining lymph nodes
from each mouse were harvested and pooled. DLN cells from each experimen-
tal group were stimulated with immunodominant CD4 and CD8 HA peptides
followed by IFN- release ELISPOT assay. Data were normalized to the mock-
stimulated positive spots for each experimental group and graphed as the number
of IFN--positive spots per 106 DLN cells. Data are presented as means plus SEM.
Values that are significantly different (P  0.05) from the value for iFlu alone by
the Mann-Whitney test are indicated by a bar and asterisk.
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vaccine alone. Postchallenge weight change relative to the starting
weight is shown in Fig. 3C to F for the first challenge experiment.
In the GVI3000 adjuvant group, one mouse showed no weight
loss, although the remaining animals lost 12% of their starting
weight on average before recovering completely; none of the mice
showed any overt clinical signs of disease. In the group given alum,
the three mice that survived the challenge showed ruffling and
hunching. Taken together, these results demonstrate that GVI3000-
adjuvanted vaccine mediated significant protection from influenza
virus-induced morbidity and mortality in neonates.
The effect of neonatal immunization on replication of chal-
lenge virus in nasal tissue was detected at 48 h postchallenge by
real-time PCR. There was a significant decrease in virus titer in the
GVI3000- and alum-adjuvanted groups compared to the iFlu-
only-immunized group when mice were challenged 5 weeks after
neonatal immunization (Fig. 4A). Additionally, we measured vi-
rus titers in the lung on day 3 postchallenge. Mice that received the
GVI3000-adjuvanted vaccine showed no detectable TCID50 titers
(level of detection  43.1 TCID50/ml), which was a reduction of
over 2 orders of magnitude compared to the titers from groups
immunized with PBS (P  0.01), iFlu only (P  0.01), and iFlu
plus alum (P  0.05) (Fig. 4B). Although the titers in the alum-
adjuvanted mice were significantly higher than those of GVI3000-
adjuvanted mice, they were significantly lower than those of iFlu-
immunized mice (P  0.05).
These results are consistent with the survival data shown in Fig.
3 and suggest that although alum provides comparable protection
early in the nose, GVI3000 adjuvant is better at preventing repli-
cation in the lungs and preventing morbidity and mortality.
GVI3000 primarily targets DCs and promotes recruitment of
multiple immune cell types into the DLNs of neonatal mice.
GVI3000 adjuvant induces recruitment and infection of APCs in
the DLNs of adult mice. Although DCs are the primary targets of
GVI3000, other immune cells are also targeted, and it is likely that
the targeting of DCs and other APCs play a role in the adjuvant
effect in adult mice (40, 46). Further investigation led to the find-
FIG 3 GVI3000-adjuvanted iFlu protects neonatally immunized mice from a lethal influenza virus challenge. Neonatal mice were immunized with iFlu only
(n  5) or with either GVI3000 (105 IU) (n  5) or alum (1:5) (n  7). Included in the challenge were PBS-immunized mice (n  8). All mice were intranasally
challenged with a lethal dose of 106 EID50 of influenza A/PR/8/34 virus at 3 weeks after immunization. (A to F) Mice were monitored for mortality (A and B) and
weight (C to F) for 7 days after the challenge.
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ings that inflammatory DCs, although rare in the DLNs during
steady state, were rapidly recruited to the site of inflammation and
were the subsets that had the largest fold increase in immune cell
population (40).
Given that the neonatal immune response is limited in part by
a reduced number of immune cells, one important question was to
determine the targets of GVI3000 in neonatal mice. Groups of five
mice were immunized in both footpads with PBS, iFlu (1 g)
alone, or iFlu together with GVI3000 expressing GFP (GVI3000-
GFP; 105 IU). GVI3000-GFP is identical to GVI3000 except that a
subgenomic promoter driving the expression of GFP has been
added downstream of NSP4. As GVI3000 cannot propagate to
surrounding cells, and as infection of and RNA replication in the
target cells must occur to allow GFP expression, cells containing
GFP unequivocally identify GVI3000 target cells that support
RNA replication (29). At 12 h postinfection (hpi), both popliteal
DLNs were harvested from each neonatal mouse, combined, and
homogenized. First, we measured the cellularity of the DLN, or
total number of cells per lymph node by flow cytometry, using the
volume analyzed by an Accuri C6 flow cytometer (BD) and back-
calculating the number of cells in the starting sample. Neonates
immunized with iFlu mixed with GVI3000-GFP had significantly
higher DLN cellularity than neonatal mice immunized with iFlu
alone (Fig. 5A). Previously published results in adult BALB/c mice
showed a similar 2- to 3-fold increase in DLN cellularity in the
presence of GVI3000 (40). Infiltrating immune cells were identi-
fied by antibody staining for the following surface markers: con-
ventional DCs (cDCs) (CD11c CD11b	), inflammatory DCs
(iDCs) (CD11c Ly6Chi) (Fig. 5B), macrophages (CD11b
CD11c	), and neutrophils (Ly6G). Except for the cDC popula-
tion, which did not differ significantly between the groups, all im-
mune cell types measured (iDCs, neutrophils, and macrophages)
showed significant population increases at 12 hpi (Fig. 5C). The same
was true for immune cell populations (B and T cells) at 24 hpi (data
not shown). Inflammatory DCs showed the most significant increase
(11-fold increase; P  0.0079), and a similar increase was observed at
12, 18, and 24 hpi (data not shown).
To determine which cell populations were targeted by
GVI3000 in the neonates, GFP-positive cells were quantified in the
DLNs at 18 hpi. Although GFP expression was observed in several
different immune cell types, iDCs were the predominant target of
GVI3000 replication (Fig. 5D). Up to two-thirds of all cells ex-
pressing GFP were iDCs. Conventional DCs, macrophages, and
neutrophils each represented 6 to 8% of all infected cells. Studies
of adult BALB/c mice showed a similar infection pattern of cell
populations (40). Approximately 11% of the GFP-positive cells
were unidentified. Previous reports and unpublished observations
in adult mice suggest that these unidentified cells may be T cells, B
cells, and NK cells (40).
GVI3000 adjuvant activates neonatal dendritic cells. The ac-
tivation and maturation of infected and bystander DCs was iden-
tified by measuring the early in vivo expression of MHCII and the
costimulatory molecules CD40, CD80, and CD86. Three groups
of four neonatal mice were immunized with PBS, iFlu (1 g)
alone, or iFlu with GVI3000-GFP (105 IU). GVI3000-GFP served
as an adjuvant to iFlu and as an expression vector for GFP. This
marker was used to distinguish the activation state of infected
versus bystander DCs in the GVI3000-adjuvanted group. Both
DLNs were harvested from each mouse, homogenized, and
stained at 18 hpi. After the cells were gated for inflammatory DCs,
they were further gated for GFP expression and analyzed for
MHCII, CD40, CD80, and CD86 (Fig. 6). The expression level of
all activation/costimulatory markers (indicated by mean fluores-
cence intensity [MFI]) observed in the iFlu-only-immunized
group did not differ from the PBS-immunized group. There were
no differences in the MFI of activation/costimulatory markers be-
tween the iDCs of the antigen-only group and the GFP-negative
iDCs in GVI3000-GFP-immunized group (Fig. 6A to D). How-
ever, iDCs that were GFP positive (i.e., GVI3000 infected) had
significantly higher MHCII, CD40, CD80, and CD86 MFIs. The
trend was similar for cDCs, with MHCII, CD80, and CD86 show-
ing significantly more GFP-positive cells than GFP-negative cells
and cDCs in the antigen-only-immunized group (data not
shown). We believe that the GFP-positive cells detected in this
experiment were due to direct infection by GVI3000-GFP and not
due to phagocytosis of infected cells. It has been previously dem-
onstrated in adult BALB/c mice that GVI3000-GFP infection leads
to uniform GFP signaling in the cytoplasm instead of punctate
GFP signaling, which would have indicated phagocytosis (36; L.
White, unpublished observations).
In summary, as seen in adult mice, GVI3000 targets and acti-
vates neonatal iDCs and cDCs. Bystander iDCs were not activated
at 18 h in the DLNs of neonates receiving GVI3000 adjuvant. This
seems to be different to what was reported ex vivo in bone mar-
FIG 4 Viral titers in nasal tissues and lungs of challenged mice. Groups of five
7-day-old mice were immunized with either iFlu (1 g) alone or with an adjuvant:
GVI3000 (105 IU) or alum (Alhydrogel [1:5]). An additional PBS-immunized
group was included. Five weeks after the single immunization, mice were chal-
lenged intranasally with 106 EID50 of influenza A/PR/8/34 virus. (A) Mice were
euthanized 48 h postchallenge, and nasal tissues were collected in TRIzol. Follow-
ing RNA extraction, real-time PCR was done with PR8 HA primer/probes. CT
values were plotted on PR8 HA standard curve to calculate virus titer. (B) Mice
were euthanized 3 days postchallenge, and their lungs were harvested. After ho-
mogenization of lung tissues, TCID50 assay was performed on MDCK cells. Cell
supernatants were collected after 48 h of incubation, and hemagglutination assay
was performed with 5% chicken red blood cells. TCID50/ml values were calculated
using the Reed-Muench method (50). All data are presented as means plus SEM.
Values that are significantly different by the Mann-Whitney test are indicated by
bars and asterisks as follows: *, P  0.05; **, P  0.01.
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row-derived DCs from adult mice, where bystander DCs were also
activated (38).
GVI3000 induces several inflammatory cytokines in neona-
tal mice early after immunization. Studies of adult mice have
shown that the GVI3000 adjuvant can significantly enhance the
inflammatory cytokine/chemokine response after immunization
(31). These effector molecules appear within a few hours and re-
turn to basal levels within 24 to 36 h after exposure to GVI3000. It
has been suggested that human neonatal plasmacytoid DCs are
incapable of inducing type I IFNs similar to adult levels (56). Sys-
temic type I IFN was induced to a high level in serum by 6 hpi in
neonatal mice immunized with GVI3000-adjuvanted flu vaccine
(Fig. 7). Furthermore, the response remains significantly higher
than in antigen-only-immunized mice at least until 24 hpi. By 36
hpi, the level of type I IFN had ebbed to near basal levels. The
kinetics of type I IFN induction is similar for the two antigens
tested (iFlu and Fluzone 2011 vaccine). The levels and kinetics of
these IFN responses were similar to those observed in control
adult BALB/c mice (data not shown), indicating that 7-day-old
mice are capable of adult-like type I IFN innate immune responses
to GVI3000-adjuvanted antigens, including both rapid induction
and return to basal levels.
To measure local induction of other inflammatory cytokines in
immunized neonatal mice, an 18-plex assay was performed mea-
suring levels of cytokine/chemokine proteins in the popliteal DLN
12 h after footpad immunization (Table 1). Several cytokines had
20- to 1,500-fold increases in the GVI3000-adjuvanted group
compared to the group immunized with antigen only, including
IFN-, interferon-inducible protein of 10 kDa (IP-10), macro-
phage chemoattractant 1 (MCP-1), and monokine induced by
IFN- (MIG). Another group of cytokines, including granulocyte
colony-stimulating factor (G-CSF), macrophage inflammatory
protein 1 (MIP-1), and RANTES (regulated on activation, nor-
mal T cell expressed and secreted) also had higher levels (5- to
15-fold) at 12 hpi. Adult DLNs analyzed at the same time showed
a very similar trend, qualitatively and quantitatively, with granu-
locyte-macrophage colony-stimulating factor (GM-CSF), IL-1,
and MIP-1 also showing 5-fold increases.
FIG 5 GVI3000 enhances inflammation in the DLNs of neonatal mice. Five 7-day-old BALB/c mice were immunized in both f.p. with PBS only or with iFlu (1
g) in the presence of 105 IU of VEE replicon particles labeled with GFP (VRP-GFP) or absence of VRP-GFP. At 12 hpi, both popliteal DLNs from each neonatal
mouse were harvested, combined, and manually disrupted into a single-cell suspension. (A) DLN cellularity was assessed by using the volume analyzed by an
Accuri C6 flow cytometer (BD) and back-calculating the starting sample amount. (B) Representative histogram for inflammatory dendritic cell gating. (C) Using
fluorescent antibody staining, immune cells were stained for DCs (CD11c), inflammatory DCs (CD11c Ly6Chi), neutrophils (Ly6G), and macrophages
(CD11c	 CD11b). The total number of each immune cell present in the DLN sample is shown in the graph. Neut, neutrophils; Macs, macrophages. (D) Cells
that were positive for GFP expression were then gated for the surface markers of different immune cells. In panels A and C, the data are presented as means plus
SEM. Values that are significantly different by the Mann-Whitney test are indicated by bars and asterisks as follows: *, P  0.05; **, P  0.01; ***, P  0.001.
Values that are not significantly different (ns) are indicated.
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DISCUSSION
The data presented here demonstrate the feasibility of a new class
of adjuvants for early life vaccination. The nonpropagating alpha-
virus replicon particle adjuvant GVI3000 was safe in neonatal
mice, and when codelivered with iFlu antigen, enhanced multiple
effector functions of the neonatal immune system, including an-
tigen-specific IgG2a antibodies, mucosal IgA, and CD4 and
CD8 T cells, indicating a shift from a TH2-polarized immune
response to a balanced TH1/TH2 immune response that potenti-
ated a significant increase in protection from a lethal influenza
virus challenge. Many of the innate immune response cytokines
and chemokines induced by GVI3000 in adult mice were also in-
duced in neonatal animals. As in adults, DCs in neonatal mice
were targeted and activated by the adjuvant particles, and a high
FIG 6 Dendritic cells are activated in VRP-GFP-adjuvanted mice. Three groups of four mice each were immunized with PBS, iFlu (2 g) only, or iFlu (2 g) with
VRP-GFP (105 IU). Immune cells from the DLNs (two per mice per pool) were harvested and stained at 18 hpi for inflammatory DCs (CD11c Ly6Chi). The
VRP-GFP-adjuvanted group had both GFP-positive (GFP ve) and GFP-negative (GFP -ve) DCs. (A to D) Inflammatory DCs were gated for MHCII (A), CD40 (B),
CD80 (C), and CD86 (D) surface markers. Data are presented as the mean fluorescence intensity (MFI)  SEM. Values that are significantly different by the Mann-
Whitney test are indicated by bars and asterisks as follows: *, P  0.05; **, P  0.01; ***, P  0.001.
FIG 7 GVI3000 induces systemic type I interferon immune response in neonatal mice. At least four 7-day-old BALB/c mice were immunized by injecting the f.p.
with Ag (iFlu; 1 g) (A) or Aĝ (Fluzone; 1 g) (B) alone or with 105 IU of GVI3000. At 3, 6, 12, 24, and 36 hpi, mice were terminally bled. Type I IFN response
was measured by IFN bioassay. Data are presented as the mean plus SEM. Values that are significantly different by the Mann-Whitney test are indicated by bars
and asterisks as follows: ***, P  0.001.
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proportion of inflammatory cells were recruited to the DLN. The
relevances of these findings are severalfold. First, it is the first
report, to our knowledge, to show a protective immune response
to influenza in a neonatal animal model, suggesting that the al-
phavirus adjuvants presumptively could be used in infants. Sec-
ond, a single immunization with the GVI3000-adjuvanted vaccine
was sufficient to protect in this model, which represents a signifi-
cant improvement over existing early life vaccines that require
multiple immunizations, including current vaccines for influenza.
This is especially relevant in poor countries, where birth and early
life are often the only opportunities for patient contact with health
care providers. Third, GVI3000 activates neonatal innate immu-
nity and enhances all arms of the adaptive immune system, in-
cluding the humoral, cellular, and mucosal compartments.
It is well established from studies of animal models and hu-
mans that the immune response to vaccination in neonates is
weaker than that of adults (2, 5, 57, 58). Vaccination in neonates is
characterized by (i) serum antibody titers that are lower in mag-
nitude (59, 60) and of shorter duration (61, 62), (ii) APCs that
show reduced upregulation of costimulatory molecules (63), (iii)
T cells that exhibit a TH2 bias, secreting high levels of IL-4 and low
levels of IFN- (2, 24, 64–66), and (iv) significantly limited cyto-
toxic T lymphocyte (CTL) responses to vaccines (reviewed in ref-
erence 5). In this study, we confirmed the age-related deficiencies
in neonatal mice relative to adult mice in different areas of the
adaptive and innate immune responses. After a single immuniza-
tion with iFlu antigen, IgG Ab titers and HAI titers in neonates
were significantly lower than those induced in adult mice. In ad-
dition, upon vaccination with antigen only, neonatal mice showed
approximately 20-fold-fewer cells in the popliteal DLN than adult
mice, including reduced numbers of iDCs, cDCs, neutrophils, and
macrophages. Furthermore, the neonatal response to antigen
alone was characterized by lower expression of most cytokines in a
panel of 18 inflammatory cytokines and chemokines examined.
Other deficiencies observed in the neonatal responses to iFlu, such
as minimal to undetectable induction of CD4 or CD8 T cells
and no mucosal IgA priming, were also present in the adult re-
sponses, and therefore, these deficiencies were in part determined
by the nature of the antigen.
Although the overall magnitude of the serum Ab titers in the
GVI3000-adjuvanted groups was still lower in neonates than in
adults, the GVI3000 adjuvant was responsible for a significant
increase in influenza virus-specific IgG antibodies, especially
IgG2a, at 3, 6, and 15 weeks, and HAI Abs at 6 weeks after a single
immunization. As seen in adult mice, GVI3000 enhanced influ-
enza virus-specific IgG2a Abs (TH1). A similar result was obtained
when neonatal mice were immunized with a GVI3000-adjuvanted
inactivated dengue virus serotype 4 vaccine. This result was in
clear contrast with the mainly IgG1 increase (TH2) observed when
the dengue virus antigen was used as an adjuvant with alum (un-
published results), highlighting the qualitative differences be-
tween the two adjuvants. In the mucosal compartment, antigen-
specific IgA was induced after two immunizations only when
GVI3000 was present in the priming inoculation, with titers that
were similar to those induced in mice primed as adults. Since we
have previously demonstrated that unadjuvanted iFlu in adult
mice does not induce mucosal IgA after one or two immuniza-
tions (J. M. Thompson and R. E. Johnston, unpublished data), our
data suggest that the induction of mucosal IgA in neonatally
primed mice is due to the primary immunization and not to the
antigen-only boost. The present study assumes that the fecal IgA
was produced at the mucosal surface (67), as has been observed
with iFlu in adults (32, 46). Therefore, the GVI3000 adjuvant may
be of particular benefit in neonatal vaccines against mucosal
pathogens. In the neonatal TH2-polarized immune response, an-
tigen-specific, IFN--producing T cells are poorly induced by im-
munization with nonreplicating antigens (5). GVI3000 was able to
overcome this deficiency after one immunization.
The presence of GVI3000 also resulted in improvement of pro-
tection in the intranasal lethal challenge model. However, in the
second challenge experiment (Fig. 3B), not only the GVI3000-
adjuvanted group but also the control unadjuvanted group had a
higher number of lethal infections than in the first challenge ex-
periment (Fig. 3A), implying that the second challenge was more
TABLE 1 Cytokine levels in the DLNs of neonatal mice at 12 hpi
Cytokine
Mean cytokine level (pg/ml  SEM) in mice immunized with the following:
Fold increase
over iFluaPBS iFlu iFlu  GVI3000
G-CSF 28.84  1.55 29.92  1.92 173.23  7.66 5.79
GM-CSF 6.90  0.57 11.21  3.72 36.02  1.64 3.21
IFN- 0.60  0.00 0.60  0.00 917.16  102.16 1,528.60*
IL-1 4.10  0.51 11.99  1.72 25.78  0.96 2.15
IL-2 28.11  1.71 30.44  0.47 33.25  1.18 1.09
IL-4 0.26  0.06 0.41  0.10 1.54  0.13 3.76
IL-5 1.02  0.52 4.94  1.83 18.37  0.91 3.72
IL-6 32.21  11.14 51.72  2.81 148.99  4.67 2.88
IL-10 7.63  4.20 9.60  3.15 20.48  2.20 2.13
IL-12p70 2.40  0.00 2.40  0.00 2.40  0.00 1.00
IP-10 79.55  7.78 99.66  11.41 2731.05  69.26 27.40*
MCP-1 8.07  2.87 11.02  3.55 230.22  18.52 20.89*
MIG 122.99  30.75 73.29  5.66 7338.89  227.30 100.13*
MIP-1 11.77  0.94 18.13  0.98 55.51  4.89 3.06
MIP-1 7.02  0.95 8.63  0.90 134.45  12.81 15.58
MIP-2 75.43  1.71 70.57  2.70 96.66  3.63 1.37
RANTES 7.02  0.93 5.63  1.05 39.78  3.14 7.07
TNF- 1.60  0.00 1.60  0.00 5.24  0.66 3.28
a Values that are statistically significantly different (P  0.05) from the value for the group immunized with iFlu are indicated by an asterisk.
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stringent than the first one. This can be explained, as the two
independent challenge experiments were performed with differ-
ent challenge stocks (live influenza virus PR8) obtained separately
from the same commercial vendor (Charles River, MA), and it is
not unexpected that minor differences in virus titers may result in
differences in virulence. Our results show that while GVI3000-
adjuvanted neonatal mice had significantly improved protection
compared to mice immunized with iFlu only, the use of alum as an
adjuvant did not improve protection, despite similar functional
HAI antibody titers at 3 weeks postimmunization. This implies
that the improved protection mediated by GVI3000 may be attrib-
uted to immune effectors other than HAI antibodies. It has been
shown previously that antibodies are effective in protection from
homologous influenza virus challenge in adult mice (68–70). It is
likely that in neonates, due to the weaker antibody response to iFlu
(even with adjuvant), those antibody levels may not be sufficient
for complete protection. Under these circumstances, and as sug-
gested by our data, cellular and mucosal immune responses, if
induced, could play a significant role in early life protection.
One of the reported deficiencies of the neonatal immune sys-
tem is the limited quantity of immune cells available compared to
adults (2, 71–75). Consistent with this, our observations show that
the cellularity of the popliteal DLN of an unimmunized 7-day-old
BALB/c mouse or an age-matched animal immunized with anti-
gen only was lower than that for a 6-week-old adult mouse. In
GVI3000 adjuvant-inoculated neonatal mice, we observed a sig-
nificant 2- to 3-fold increase of DLN cellularity, which was similar
to the percentage increase in cellularity induced by GVI3000 in
adult mice reported by Tonkin et al. (40). Additionally, we ob-
served that the total number of iDCs in GVI3000-adjuvanted neo-
natal DLNs accounted for approximately 8% of the total number
of cells in the DLN, while it was 2% in the adult DLN (40). The
robust recruitment and targeting of iDCs suggest an important
role for these cells in the mediation of the GVI3000 adjuvant ef-
fect. DCs have been shown to be sufficient to mediate the GVI3000
adjuvant effect (40), but it is possible that other cell types comple-
ment the role of iDCs. We therefore cannot definitively point to a
specific cell type that mediates the immune enhancement driven
by GVI3000, but we predict that the ability of GVI3000 to trigger
cell recruitment in neonates is an important component of this
outcome.
We hypothesized that, as in adult mice, the adjuvant effect of
GVI3000 in neonates was associated with the ability to (i) target
and activate neonatal DCs and (ii) induce a robust TH1 innate
immune response. Previous in vitro studies using VEE replicon
particles (VRP) expressing GFP to infect adult human (38) and
murine bone marrow-derived DCs (BMDCs) (37) showed an up-
regulation in costimulatory molecules CD40, CD80, and CD86.
Additional studies using VRP-transduced human DCs showed
DC maturation, secretion of proinflammatory cytokines, and sig-
nificant expansion of antigen-specific T cells (38). In our in vivo
system, we observed that both conventional and inflammatory
DCs had significantly higher expression of MHCII, CD40, CD80,
and CD86 after administration of GVI3000. However, this in-
crease was observed only in DCs that were GVI3000 positive (GFP
positive), but not in the “bystander DCs.” These results indicate
that the infected DCs are the primary driver of the adjuvant effect
of GVI3000 in the neonates. This finding is in contrast to what was
described in in vitro studies of adult DCs, where both GVI3000-
infected and bystander DCs showed upregulation of those mark-
ers (38). We can speculate that the absence of activation of by-
stander DCs in neonates at the time points examined may
contribute to the reduced magnitude of the immune responses in
neonates compared to adults. On the other hand, we cannot rule
out the possibility that the “bystander” DCs would show a signif-
icant increase in expression of maturation and costimulatory mol-
ecules if examined at later times, after 18 h, as was observed in vitro
at 24 h postinfection of human DCs (38). Further studies are
needed to better understand the kinetics of DC maturation and
expression of costimulatory molecules in vivo and its effect on
T-cell response.
Our second hypothesis was that the significantly improved hu-
moral and cellular GVI3000 adjuvant effect was associated with a
robust TH1 cytokine response initiated early after immunization.
Consistent with this hypothesis, a rapid, strong, and self-limited
innate immune response was observed locally and systemically
upon GVI3000 immunization, based on the rapid cytokine induc-
tion. The innate immune responses were consistent even when
other antigens were used (data not shown), indicating that the
GVI3000 adjuvant was primarily responsible for the enhanced
response.
Our results indicate that GVI3000 can induce adult-like sys-
temic and local innate immune responses in neonates. Although
type I IFN function is not required for the adjuvant activity of
GVI3000 in adult mice (51), it is an indicator of GVI3000 RNA
replication and of a robust innate immune response. The obser-
vation that neonatal mice had adult-level type I IFN responses to
GVI3000 indicates that the adjuvant may overcome the impair-
ment in type I IFN induction observed in newborn cord blood (76,
77). Additionally, the type I IFN response was systemic, peaking at
12 h postimmunization and falling to the background level by 36
h. This demonstrates that the GVI3000-mediated inflammatory
response is transient, reducing any chance of prolonged inflam-
mation or toxicity. One of the reasons for immunizing neonatal
mice in the footpad was the ability to investigate the process of
inflammation in a single DLN. The results of cytokine expression
analysis in the DLN further supported our second hypothesis in
that the enhanced cellular immune response is preceded by a TH1-
promoting innate immune response. As with systemic type I IFN
expression, a similar pattern of peak expression of most cytokines
at 12 hpi was observed with gradual reduction to the background
level by 36 hpi (data not shown).
IFN- is a hallmark of a TH1 response; however, its production
is impaired in newborns, as evidenced by the lack of IFN- induc-
tion in neonatal mice after subcutaneous injection of lipopolysac-
charide (LPS) (78). BCG vaccination is one of the few examples of
vaccines that can induce adult-like IFN- as has been demon-
strated in CD4 T cells of 2-month-old human newborns that had
been immunized at birth after stimulation with a mycobacterial
purified protein derivative (79). IFN- protein expression was
rapidly upregulated in neonatal mice after GVI3000 inoculation,
which induced an adult-like response (adult data not shown). The
IFN--responsive chemokine IP-10 (chemokine [C-X-C motif]
ligand 10 [CXCL10]) (80) was significantly upregulated in
GVI3000-adjuvanted neonatal mice to a level similar to that in
adult animals. As observed in adult mice, GVI3000 did not induce
IL-12 protein expression, even though this cytokine is strongly
associated with induction of IFN- and a TH1 response. There-
fore, further investigation is needed to elucidate the role of IL-12,
or lack thereof, in the GVI3000 adjuvant mode of action. Other
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cytokines that were upregulated but do not have a clearly defined
role in TH1 responses were MCP-1, MIG, and MIP-1. Overall,
the cytokine expression pattern between neonates and adults was
quite similar, indicating the following. (i) Neonates are capable of
mounting an adult-like innate immune response. (ii) The mech-
anism whereby the GVI3000 adjuvant induces innate immune
response may be similar in neonates and adults.
Improved technologies are urgently needed for vaccines
against several infectious diseases, especially those affecting chil-
dren in developing countries. This study demonstrates the poten-
tial of GVI3000 for early life vaccination.
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